FLASHDOSE

Dead / Abandoned — Abandoned — no statement of use filed (as of 24 Aug 2009)

What this means for you

This application is over — abandoned 24 Aug 2009. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
78543928
Mark type
Stylized text
Filed
07 Jan 2005
Published for opposition
02 May 2006
Abandoned
24 Aug 2009
Attorney of record
James R. Menker

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan

Owner

Prior registrations

Prosecution history

  • 13 Oct 2010 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
  • 24 Aug 2009 — ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
  • 24 Aug 2009 — ABANDONMENT - NO USE STATEMENT FILED
  • 17 Jun 2009 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
  • 05 Feb 2009 — SOU EXTENSION 5 GRANTED
  • 22 Jan 2009 — SOU EXTENSION 5 FILED
  • 05 Feb 2009 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 22 Jan 2009 — SOU TEAS EXTENSION RECEIVED
  • 22 Jan 2009 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 22 Jan 2009 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 17 Jul 2008 — SOU EXTENSION 4 GRANTED
  • 17 Jul 2008 — SOU EXTENSION 4 FILED
  • 17 Jul 2008 — SOU TEAS EXTENSION RECEIVED
  • 07 Feb 2008 — SOU EXTENSION 3 GRANTED
  • 18 Jan 2008 — SOU EXTENSION 3 FILED

View this trademark record on Marksy